Correlation of demographic, histological and molecular characteristics and clinical course of the disease in patients with lung adenocarcinoma

Correlation of demographic, histological and molecular characteristics and clinical course of the disease in patients with lung adenocarcinoma

Aim Retrospective analysis of disease clinical course with a purpose of defining potential prognostic parameters which are essential for optimal target therapy. Methods The study involved 29 patients with histologically confirmed lung adenocarcinoma and existing epidermal growth factor receptor (...

Full description

Bibliographic Details
Main Authors:	Lora Novaković Lacković, Ljilja Latinović Tadić, Mirko Stanetić, Nataša Tanasković, Slavica Marić, Marko Lacković
Format:	Article
Language:	English
Published:	Medical Association of Zenica-Doboj Canton 2019-08-01
Series:	Medicinski Glasnik
Subjects:	epidermal growth factor mutation reaction time receptor
Online Access:	http://ljkzedo.ba/mgpdf/mg31/13_Novakovic_Lackovic_1003_A.pdf

Similar Items

Detection and Analysis of EGFR and KRAS Mutation with Lung Adenocarcinoma
by: Hui ZHANG, et al.
Published: (2015-11-01)

Relationship of epidermal growth factor receptor activating mutations with histologic subtyping according to International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society 2011 adenocarcinoma classification and their impact on overall survival
by: Venkata Nagarjuna Maturu, et al.
Published: (2016-01-01)

Radiomics Signature as a Predictive Factor for EGFR Mutations in Advanced Lung Adenocarcinoma
by: Duo Hong, et al.
Published: (2020-01-01)

EGFR Mutation Status in Uighur Lung Adenocarcinoma Patients
by: Li SHAN, et al.
Published: (2013-02-01)

Reporting of Incidence and Outcome of Bone Metastases in Clinical Trials Enrolling Patients with Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma—A Systematic Review
by: Anita Brouns, et al.
Published: (2021-06-01)

Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study
by: Dinesh Chandra Doval, et al.
Published: (2013-01-01)

Computed Tomography Morphological Classification of Lung Adenocarcinoma and Its Correlation with Epidermal Growth Factor Receptor Mutation Status: A Report of 1075 Cases
by: Li Q, et al.
Published: (2021-07-01)

Multiple primary lung adenocarcinomas pre‐operatively diagnosed by discordant epidermal growth factor receptor mutations
by: Yuki Katayama, et al.
Published: (2019-08-01)

Histologic Transformation in EGFR-Mutant Lung Adenocarcinomas: Mechanisms and Therapeutic Implications
by: Ranjan Pathak, et al.
Published: (2021-09-01)

Correlation between high-resolution computed tomography lung nodule characteristics and EGFR mutation in lung adenocarcinomas
by: Nie Y, et al.
Published: (2019-01-01)

Modified Restriction Enzyme-based Detection of EGFR Mutations in Lung Cancer
by: Fan YANG, et al.
Published: (2011-08-01)

Epidermal growth factor receptor and anaplastic lymphoma kinase mutation in adenocarcinoma lung: Their incidence and correlation with histologic patterns
by: Pankaj Gupta, et al.
Published: (2019-01-01)

A Case Report Demonstrating the Potential Clinical Relevance of Liquid Tumor Biopsies in Lung Cancer
by: Revathi Suppiah, et al.
Published: (2016-11-01)

Associations of <i>TIMP-3</i> Genetic Polymorphisms with <i>EGFR</i> Statuses and Cancer Clinicopathologic Development in Lung Adenocarcinoma Patients
by: Jer-Hwa Chang, et al.
Published: (2020-10-01)

Membrane-bound estrogen receptor-α expression and epidermal growth factor receptor mutation are associated with a poor prognosis in lung adenocarcinoma patients
by: Shimizu Katsuhiko, et al.
Published: (2012-07-01)

De Novo T790M Mutation in an L858R Epidermal Growth Factor Receptor Mutant-Associated Lung Adenocarcinoma
by: Takumi Fujiwara, et al.
Published: (2020-10-01)

Deep CNN Model Using CT Radiomics Feature Mapping Recognizes EGFR Gene Mutation Status of Lung Adenocarcinoma
by: Baihua Zhang, et al.
Published: (2021-02-01)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
by: Yuan Ying, et al.
Published: (2012-11-01)

Epidermal Growth Factor Receptor Mutations and Radiotherapy  in Non-small Cell Lung Cancer
by: Xing ZHONG, et al.
Published: (2013-03-01)

Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
by: Sheng-Kai Liang, et al.
Published: (2021-01-01)

Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives
by: Mauro Zükin
Published: (2012-04-01)

EGFR Gene Mutation Statuses in Advanced Non-small Cell Lung Cancer Patients and Their Influence on Effect of Gefitinib
by: Wei ZHONG, et al.
Published: (2012-09-01)

Lung adenocarcinoma and adrenocortical carcinoma in a patient with multiple endocrine neoplasia type 1
by: Nobumasa Ohara, et al.
Published: (2017-01-01)

Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations
by: Zhengyu Yang, et al.
Published: (2021-08-01)

Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma
by: Shouzheng Wang, et al.
Published: (2021-10-01)

Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I and G724S: A case report and literature review
by: Cuicui Zhang, et al.
Published: (2020-09-01)

Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey
by: Sang Hwa Lee, et al.
Published: (2015-11-01)

Distribution Of Brain Metastasis From Lung Cancer
by: Wang G, et al.
Published: (2019-11-01)

Research Progress of Targeted Therapy for EGFR Gene in Non-small Cell Lung Cancer
by: Hui ZHANG, et al.
Published: (2017-01-01)

Clinical Value of Droplet Digital PCR and Super-ARMS Detection of Epidermal Growth Factor Receptor Gene Mutation in Plasma Circulating Tumor DNA of Patients with Advanced Lung Adenocarcinoma
by: Zhe CAO, et al.
Published: (2020-02-01)

An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
by: Shang-Gin Wu, et al.
Published: (2020-09-01)

Upfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma
by: Li C, et al.
Published: (2019-04-01)

Diffuse Lung Metastases in <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer
by: Subba R. Digumarthy, et al.
Published: (2019-09-01)

Analysis of the Efficacy of Immunotherapy on the Posterior Lines  of Advanced EGFR Mutant Patients with Non-small cell Lung Cancer
by: Li MA, et al.
Published: (2021-05-01)

Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery
by: Tetsuya Isaka, et al.
Published: (2018-10-01)

Unmet Medical Needs in Non-Small-Cell Lung Cancer Treatment: How to Design Pre-Emptive Combination Therapies
by: Niki Karachaliou, et al.
Published: (2014-11-01)

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
by: Wang Wen-Ping, et al.
Published: (2012-01-01)

A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition
by: Nana Zhang, et al.
Published: (2017-01-01)

Detection and Analysis of EGFR and KRAS Mutations  in the Patients with Lung Squamous Cell Carcinomas
by: Hui ZHANG, et al.
Published: (2015-10-01)

Our Experiences with Erlotinib in Second and Third Line Treatment Patients with Advanced Stage Iiib/ Iv Non-Small Cell Lung Cancer
by: Bakir Mehić, et al.
Published: (2008-11-01)